Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Wednesday Morning

May 20, 2026 08:54:01

Shares of Immunovant, Inc. (NASDAQ: IMVT) traded at a new 52-week high today and are currently trading at $28.94. So far today, approximately 1.82M shares have been exchanged, as compared to an average 30-day volume of 1.4M shares.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials.

Immunovant, Inc. share prices have moved between a 52-week high of $30.09 and a 52-week low of $13.52. The stock has moved -9.22% over the past week.

To learn more, visit Immunovant, Inc.

Receive IBN News Alerts – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN News Alerts, please visit https://IBN.fm/connected

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]